-

01:17:33 AM

Latest JAZZ Stock Market News

JAZZ - JAZZ

09/13/21 4:15 PM

Nasdaq : JAZZ

Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Xywav ® (calcium, magnesium, potassium and sodium oxybates), the first and only

RHEA-AI

neutral

09/08/21 4:15 PM

Nasdaq : JAZZ

conferences

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences:BofA Virtual Global Healthcare Conference 2021 on Wednesday, September 15, 2021The presentation will be available

RHEA-AI

neutral

08/12/21 2:30 PM

Nasdaq : JAZZ

fda approval

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav ® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults. 1 The company

RHEA-AI

neutral

08/10/21 8:00 AM

Nasdaq : JAZZ

Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers

Stand Up To Cancer ® (SU2C) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announce a three-year, $4 million research collaboration to explore new opportunities, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and

RHEA-AI

positive

08/10/21 4:24 AM

Nasdaq : JAZZ

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

GW Pharmaceuticals ("GW"), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines and now part of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), today announces that the UK Medicines and Healthcare Products Regulatory

RHEA-AI

very positive

08/03/21 4:05 PM

Nasdaq : JAZZ

earnings

Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2021 and affirmed non-GAAP adjusted financial guidance for 2021. "As we enter what we expect to be a period of sustained growth, I have never been more excited

RHEA-AI

positive

07/22/21 4:15 PM

Nasdaq : JAZZ

National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network ® (NCCN) added Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Acute

RHEA-AI

very positive

07/20/21 4:15 PM

Nasdaq : JAZZ

conferencesearnings

Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 second quarter financial results on Tuesday, August 3, 2021 after the close of the financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30

RHEA-AI

neutral

07/13/21 4:15 PM

Nasdaq : JAZZ

Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 20, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), which was approved by

RHEA-AI

neutral

06/30/21 8:04 PM

Nasdaq : JAZZ

fda approval

Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze ™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of

RHEA-AI

very positive

1 2 3 4 5 6 Next